Axsome Therapeutics, Inc.

AXSM · NASDAQ

AXSM has an annual revenue baseline of $638.5M, latest revenue marker of $191.2M Q1 2026, annual net income of -$183.2M and cash of $305.1M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.

Follow Add to Watchlist Ask Question

NASDAQ AXSM Coverage Bootstrap Nasdaq Axsome Therapeutics, Inc.

Latest ReportMay 20, 2026Axsome Therapeutics: the neuroscience growth story still has to outrun losses and cash burnView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.